Daniel F Hogan1, Philip R Fox2, Kristin Jacob3, Bruce Keene4, Nancy J Laste5, Steven Rosenthal3, Kimberly Sederquist6, Hsin-Yi Weng7. 1. Purdue University, College of Veterinary Medicine, Department of Veterinary Clinical Sciences, 625 Harrison Street, West Lafayette, IN 47907-2026, USA. Electronic address: hogandf@purdue.edu. 2. Caspary Institute, The Animal Medical Center, 510 East 62nd Street, New York, NY 10065, USA. 3. CVCA-Cardiac Care for Pets, 1209 Cromwell Bridge Road, Towson, MD 21286, USA. 4. North Carolina State University, College of Veterinary Medicine, Department of Clinical Sciences, 1060 William Moore Drive, Raleigh, NC 27607, USA. 5. MSPCA-Angell Animal Medical Center, 350 South Huntington Ave., Boston, MA 02130, USA. 6. Purdue University, College of Veterinary Medicine, Veterinary Teaching Hospital, 625 Harrison Street, West Lafayette, IN 47907-2026, USA. 7. Purdue University, College of Veterinary Medicine, Department of Comparative Pathobiology, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
Abstract
OBJECTIVES: To determine if clopidogrel administration is associated with a reduced likelihood of recurrent cardiogenic arterial thromboembolism (CATE) in cats compared to aspirin administration. Secondary aims were to determine if clopidogrel administration had an effect on the composite endpoint of recurrent CATE and cardiac death and to identify adverse effects of chronic clopidogrel or aspirin therapy. ANIMALS: Seventy-five cats that survived a CATE event. METHODS: Multicenter, double-blind, randomized, positive-controlled study. Cats were assigned to clopidogrel (18.75 mg/cat PO q 24 h) or aspirin (81 mg/cat PO q 72 h). Kaplan-Meier survival curves were created for each endpoint and the log rank test performed to compare treatment groups with respect to time to event and the likelihood of the event occurring. RESULTS: The mean age of all cats was 8.0 ± 3.5 yr and 57/75 (76%) were male (p < 0.001); 62/75 (83%) were mixed breed with the remainder including Persian, Abyssinian, American Shorthair, Bengal, Birman, Himalayan, Maine Coon, Ragdoll, Snowshoe, and Sphynx breeds. Only 15% (11/75) of cats had a history of heart disease recorded prior to the CATE event. Clopidogrel administration was associated with significantly reduced likelihood of recurrent CATE compared to aspirin (p = 0.024) and had a longer median time to recurrence [443 (95% CI 185-990) days vs. 192 (95% CI 62-364) days, respectively]. Clopidogrel was also associated with a significantly reduced likelihood of the composite endpoint of recurrent CATE or cardiac death (p = 0.033) with a longer median time to event [346 (95% CI 146-495) days vs. 128 (95% CI 58-243) days]. CONCLUSIONS: Clopidogrel administration significantly reduces the likelihood of recurrent CATE compared with aspirin in cats; both drugs were well tolerated.
OBJECTIVES: To determine if clopidogrel administration is associated with a reduced likelihood of recurrent cardiogenic arterial thromboembolism (CATE) in cats compared to aspirin administration. Secondary aims were to determine if clopidogrel administration had an effect on the composite endpoint of recurrent CATE and cardiac death and to identify adverse effects of chronic clopidogrel or aspirin therapy. ANIMALS: Seventy-five cats that survived a CATE event. METHODS: Multicenter, double-blind, randomized, positive-controlled study. Cats were assigned to clopidogrel (18.75 mg/cat PO q 24 h) or aspirin (81 mg/cat PO q 72 h). Kaplan-Meier survival curves were created for each endpoint and the log rank test performed to compare treatment groups with respect to time to event and the likelihood of the event occurring. RESULTS: The mean age of all cats was 8.0 ± 3.5 yr and 57/75 (76%) were male (p < 0.001); 62/75 (83%) were mixed breed with the remainder including Persian, Abyssinian, American Shorthair, Bengal, Birman, Himalayan, Maine Coon, Ragdoll, Snowshoe, and Sphynx breeds. Only 15% (11/75) of cats had a history of heart disease recorded prior to the CATE event. Clopidogrel administration was associated with significantly reduced likelihood of recurrent CATE compared to aspirin (p = 0.024) and had a longer median time to recurrence [443 (95% CI 185-990) days vs. 192 (95% CI 62-364) days, respectively]. Clopidogrel was also associated with a significantly reduced likelihood of the composite endpoint of recurrent CATE or cardiac death (p = 0.033) with a longer median time to event [346 (95% CI 146-495) days vs. 128 (95% CI 58-243) days]. CONCLUSIONS:Clopidogrel administration significantly reduces the likelihood of recurrent CATE compared with aspirin in cats; both drugs were well tolerated.
Authors: Sara T Lo; Ashley L Walker; Catherine J Georges; Ronald Hl Li; Joshua A Stern Journal: J Feline Med Surg Date: 2021-05-10 Impact factor: 2.015
Authors: Mackenzie Ruehl; Alex M Lynch; Therese E O'Toole; Bari Morris; John Rush; C Guillermo Couto; Samantha Hmelo; Stacey Sonnenshein; Amy Butler; Julien Guillaumin Journal: J Vet Intern Med Date: 2020-08-15 Impact factor: 3.333
Authors: Karsten E Schober; John E Rush; Virginia Luis Fuentes; Tony Glaus; Nuala J Summerfield; Kathy Wright; Linda Lehmkuhl; Gerhard Wess; Margaret P Sayer; Joao Loureiro; John MacGregor; Nicole Mohren Journal: J Vet Intern Med Date: 2021-02-05 Impact factor: 3.333
Authors: Virginia Luis Fuentes; Jonathan Abbott; Valérie Chetboul; Etienne Côté; Philip R Fox; Jens Häggström; Mark D Kittleson; Karsten Schober; Joshua A Stern Journal: J Vet Intern Med Date: 2020-04-03 Impact factor: 3.333
Authors: Samantha L Kochie; Karsten E Schober; Jaylyn Rhinehart; Randolph L Winter; John D Bonagura; Annie Showers; Vedat Yildez Journal: J Vet Intern Med Date: 2020-11-26 Impact factor: 3.175